JnJ gets USFDA nod for Rybrevant plus standard of care chemotherapy for lung cancer treatment Ruchika Sharma21 Sept 2024 4:00 PM ISTRaritan: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved RYBREVANT (amivantamab-vmjw) in...
JnJ chemotherapy free lung cancer treatment Rybrevant plus Lazcluze gets USFDA okay Ruchika Sharma21 Aug 2024 12:30 PM ISTNew Jersey: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved RYBREVANT (amivantamab-vmjw) plus...
USFDA nod to JnJ for Rybrevant, Chemotherapy combo for lung cancer treatment Anshika Mishra4 March 2024 5:09 PM ISTJohnson & Johnson has announced that following a priority review, the U.S. Food and Drug Administration (FDA) has approved RYBREVANT...
Health Bulletin 04/ March/ 2024 Anshika Mishra4 March 2024 4:44 PM ISTHere the top health news for the day :Lady hardinge medical college to introduce new DNB and FNB courses soon Bringing good news to the postgraduate...
Johnson and Johnson gets USFDA approval for Rybrevant, chemotherapy combo for lung cancer treatment Ruchika Sharma2 March 2024 2:33 PM ISTRaritan: Johnson & Johnson has announced that following a priority review, the U.S. Food and Drug Administration (FDA) has approved RYBREVANT...
JnJ seeks USFDA nod for Rybrevant plus Lazertinib for EGFR-Mutated Non-Small Cell Lung Cancer Ruchika Sharma24 Dec 2023 12:30 PM ISTRaritan: Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
Janssen seeks USFDA nod for Rybrevant plus chemotherapy for patients with EGFR-Mutated Non-Small Cell Lung Cancer who progressed on or after Osimertinib Ruchika Sharma23 Nov 2023 2:30 PM ISTRaritan: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a supplemental Biologics License ...
Phase 3 Mariposa study evaluating Rybrevant plus Lazertinib meets primary endpoint in PFS in Non-Small Cell Lung Cancer: Janssen Ruchika Sharma2 Oct 2023 10:00 AM ISTRartan: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced positive topline results from the Phase 3 MARIPOSA study...
Janssen declares positive topline results from Phase 3 study evaluating RYBREVANT given with, without lazertinib combined with chemotherapy versus chemotherapy alone Ruchika Sharma9 Sept 2023 1:45 PM ISTNew Jersey: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced positive topline results from the three-arm Phase 3 ...
Janssen seeks expanded USFDA approval for Rybrevant in combination with chemotherapy Ruchika Sharma29 Aug 2023 12:00 PM ISTRaritan: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a supplemental Biologics License ...
Phase 3 trial of Rybrevant plus chemotherapy in lung cancer meets primary endpoint: Janssen Ruchika Sharma18 July 2023 1:30 PM ISTNew Jersey: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced positive topline results from the Phase 3 PAPILLON study ...
